Search Intelligence

“Beating individual generalists on specialist-level cases makes for a great headline, but the study's own data shows the base GPT-5 and GPT-5.5 models do most of the heavy lifting while Microsoft's wrapper mainly trims a multi-thousand-dollar per-case compute bill.”

“While escaping a domestic shareholder inquiry is a critical win for Philips leadership, the company still faces an active fraud probe in France regarding the recalled medical devices.”

“Paying a 44.8% premium for a pain therapy portfolio is a classic pharma move to buy immediate financial accretion when internal pipeline innovation isn't enough.”

“Mind-reading AI is technically impressive, but until researchers compress these models to work on a cheap EEG headset instead of a multi-million-dollar fMRI machine, your thoughts are safe from corporate data brokers.”

“Pledging billions in future domestic capex is just the modern corporate playbook for buying immunity from federal import tariffs.”

“Hardware vendors lending billions to their own customers to buy their own chips isn't a healthy ecosystem—it's a telecom-era debt trap waiting for a single default.”

“Anthropic is happy to power OpenEvidence's global expansion today, masking the reality that frontier labs are actively learning how to eventually replace these vertical clinical startups entirely.”

“Automating lease reminders and clinic scheduling is fundamentally unglamorous software, but VCs will happily pump billions into anything replacing human administrative bloat.”

“The most immediate and lucrative use case for enterprise AI in healthcare isn't saving lives, it's simply automating the extraction of billions from insurers without changing actual patient treatment.”

“Charging a $149 toll for a software-based medical feature is a brutally effective way to extract healthcare margins from consumer electronics.”

“Apple realized the only way to squeeze more subscription revenue out of health tracking is to sell a device to people who refuse to wear smartwatches.”

“When Medicare starts footing the bill for weight loss drugs, the pharma company that secures the first-mover advantage essentially locks in a permanent pipeline of taxpayer cash.”

“Locking up an independent isotope manufacturer for $2.35B proves that in modern biotech, owning the physical supply chain is vastly more valuable than just owning the IP.”

“Releasing an expert-level diagnostic model as open-source isn't just charity; it's a brute-force strategy to bypass legacy medical software vendors and dominate global hospital workflows.”

“Rebranding and buying up API access to every major frontier lab is the standard corporate playbook when your core obesity market share starts slipping.”

“Big Tech labs get to deploy in the Global South and harvest non-Western language data while a foundation covers the massive rollout bill.”

“You can spend millions locking down your internal servers, but it means nothing if a vendor's stolen credentials give attackers direct API access to patient SSNs.”

“Enterprise security failures aren't just IT headaches anymore—they're the fastest way to wipe out a year of financial guidance in a single quarter.”

“Pharma's favorite strategy of buying their way out of a patent cliff hits a wall when the acquired pipeline repeatedly faceplants in Phase 3.”

“Healingpaper's recent global expansion strategy is now severely threatened by the immediate need for international trust recovery.”